Evidence map›Paper›PMID 40189613›Full record

ArticleScientific reports2025

Naringin attenuates angiotensin II induced cardiac hypertrophy by inhibiting carbonic anhydrase II.

Mahendra Mahadevaswamy, G P Suchitha, S R Pavan, H K Vivek, S D Nithya, S Chandan, Shashanka K Prasad, T S Keshava Prasad, Sheikh F Ahmad, Sabry M Attia and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Cardioprotective Potential ofCurrent drug targets · 2026
    Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Mahendra MahadevaswamyDivision of Biochemistry, School of Life Sciences, JSS Academy of Higher Education & Research, SS Nagar, Mysuru, 570015, India.
G P SuchithaCenter for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India.
S R PavanYenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India.
H K VivekDepartment of Biotechnology, Adichunchanagiri School of Natural Sciences, ACU-CRI, Adichunchanagiri University, B. G. Nagara, Karnataka, 571448, India.
S D NithyaDivision of Biochemistry, School of Life Sciences, JSS Academy of Higher Education & Research, SS Nagar, Mysuru, 570015, India.
S ChandanDepartment of Biotechnology & Bioinformatics, JSS Academy of Higher Education & Research, SS Nagar, Mysuru, 570015, India.
Shashanka K PrasadDepartment of Biotechnology & Bioinformatics, JSS Academy of Higher Education & Research, SS Nagar, Mysuru, 570015, India.
T S Keshava PrasadCenter for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India.
Sheikh F AhmadDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Sabry M AttiaDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Shobha DagamajaluCenter for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India. shobha_d@yenepoya.edu.in.
Jalahalli M SiddeshaDivision of Biochemistry, School of Life Sciences, JSS Academy of Higher Education & Research, SS Nagar, Mysuru, 570015, India. siddeshajm@jssuni.edu.in.

Funding

Department of Science and Technology, Ministry of Science and Technology SRG/2021/001016JSS Academy of Higher Education and Research JSSAHER/REG/RES/URG/54/2023-24King Saud University, Riyadh, Saudi Arabia RSPD2024R709
6 · The paper itself

Abstract

Nutraceuticals exert a series of health benefits, including protection against cardiovascular diseases. In this study, naringin, naringenin, and quercetin were tested for their safety and efficacy in ameliorating angiotensin (Ang) II-induced cardiac hypertrophy through carbonic anhydrase II (CA-II) inhibition. In silico molecular docking and MD simulations exhibited that naringin strongly binds CA-II with a docking score of -9.55 kcal/mol and hydrogen bonding energy of -6.07 kcal/mol. Naringin formed stable hydrogen bond interactions with Asn62, Trp5, and N-acetyl His4 via catalytic water molecule, and a continuous interaction via major water bridge with N-acetyl His4, His4, and Trp5. Moreover, naringin effectively inhibited CA-II activity with an IC

Indexed as

Angiotensin IICarbonic Anhydrase IICarbonic Anhydrase InhibitorsCardiomegalyFlavanonesAnimalsCell LineCell SurvivalMolecular Docking SimulationMyocytes, CardiacQuercetinRatsSodium-Hydrogen Exchanger 1Angiotensin IICarbonic Anhydrase IICarbonic Anhydrase InhibitorsFlavanonesnaringeninnaringinQuercetinSodium-Hydrogen Exchanger 1CA-IICardiac hypertrophyNaringinNCX1NHE1Nutraceuticals

Identifiers

PMID40189613
PMCPMC11973137

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.